Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GRFS with free AI briefings, catalyst countdowns, and dilution alerts.

GRFS · Grifols SA

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$486M Cash on Hand
CF+ Cash Runway
Follow GRFS by email Get an email when GRFS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GRFS, unsubscribe in one click. Privacy

📣 What GRFS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
von Willebrand Factor Hemophilia A, Congenital Phase 2 · NCT03095287 Terminated
plasma-derived FVIII/VWF concentrate Von Willebrand Disease Phase 4 · NCT02472665 Withdrawn
Therapeutic Immune Globulin Primary Immunodeficiency Phase 4 · NCT04566692 Completed
Alphanate SD/HT Von Willebrand Disease Phase 4 · NCT00555555 Terminated
Coagulation Factor VIII Hemophilia A Phase 4 · NCT04621916 Unknown
Human Immunoglobulin G CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) Phase 3 · NCT07540221 Recruiting
Immune Globulin Subcutaneous Human CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) Phase 3 · NCT07540221 Recruiting
SMT + PE-A 5% Acute-On-Chronic Liver Failure Phase 3 · NCT03702920 Terminated
Plasma-derived AT-III concentrate Antithrombin III Deficiency Phase 2/3 · NCT00319228 Terminated
IVIG-PEG Primary Immunodeficiency Phase 3 · NCT04561115 Completed
0.9% sodium chloride COVID-19 Phase 3 · NCT04847141 Terminated
Fibrin Sealant Grifols Excessive Bleeding During Surgery Phase 3 · NCT03461406 Completed
EVICEL Excessive Bleeding During Surgery Phase 3 · NCT03461406 Completed
Fibrinogen Congenital Afibrinogenemia Phase 3 · NCT04636268 Withdrawn
C19-IG 20% COVID-19 Phase 3 · NCT04847141 Terminated
Albutein 20% Decompensated Cirrhosis and Ascites Phase 3 · NCT03451292 Completed

Also used in these trials (approved or third-party drugs, not GRFS's own candidates): Emicizumab, Methotrexate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GRFS holds $486M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRFS files for a raise →

Get the full GRFS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRFS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.